GT BIOPHARMA, INC.
Income Statement
| Line Item | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $27.0K | $61.0K | $368.0K | $342.0K |
| Cost of Revenue | — | — | $0 | $0 | $0 | $57.0K | $226.0K | $94.0K |
| Gross Profit | — | — | $0 | $0 | $27.0K | $4.0K | $142.0K | $248.0K |
| Gross Margin | — | — | — | — | 100.0% | 6.6% | 38.6% | 72.5% |
| Operating Expenses | ||||||||
| Research & Development | $485.0K | $1.7M | $1.1M | $975.0K | $1.0M | $0 | $0 | $0 |
| SG&A Expense | $6.3M | $9.8M | $134.5M | $8.4M | $8.0M | $2.4M | $935.0K | $3.4M |
| Operating Income | $-6.8M | $16.1M | $-135.6M | $-9.4M | $-8.9M | $-2.4M | $-793.0K | $-3.5M |
| Operating Margin | — | — | — | — | -33,063.0% | -3,927.9% | -215.5% | -1,027.5% |
| Interest Expense | $-3.0M | $-2.1M | $8.6M | $6.6M | $17.0M | $5.1M | $1.2M | $1.7M |
| Pretax Income | — | $-38.6M | $-144.2M | $9.8M | $-21.5M | $-23.5M | $-564.0K | $-5.3M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-28.3M | $-38.6M | $-144.2M | $9.8M | $-21.5M | $-23.5M | $-501.0K | $-5.2M |
| Net Margin | — | — | — | — | -79,485.2% | -38,506.6% | -136.1% | -1,512.0% |
| EPS (Basic) | $-0.36 | $0.00 | $-0.01 | $0.10 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.36 | $0.00 | $-0.01 | $0.10 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | — | — | 20.22B | 29.46B | 28.88B | 7.14T | 6.91T | 6.04T |
| Shares Outstanding (Diluted) | 78.9M | 60.9M | 20.22B | 29.46B | 28.88B | 7.14T | 6.91T | 6.04T |
| Dividends Per Share | — | — | — | — | — | — | — | — |